Algorithm for the treatment of schizophrenia in Japan

International Journal of Psychiatry in Clinical Practice

Volumn 3, Issue 4, 1999, Pages 271-276

  Sato, M ^a   Nakane, N ^b   Hayashida, M ^b   Koshino, Y ^c   Uchimura, H ^d   Tsutsumi, T ^d   Koyama, T ^e   Kusumi, I ^e   Akiyama, K ^f   Saito, H ^g   Saijo, T ^g   Ito, C ^a   Kubota, Y ^a   Nishikawa, T ^h   Kuroda, Y ^h   Hamamura, T ^f   Fujiwara, Y ⁱ   Higuchi, T ^j   Yamawaki, S ^k  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d Hizen National Mental Hospital   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

^f OKAYAMA UNIVERSITY   (Japan)

^g National Hospital Organization Hanamaki Hospital   (Japan)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

ⁱ Takaoka Hospital   (Japan)

^j SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^k HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute schizophrenic episode; International Psychopharmacology Algorithm; Japan Psychomarcology Algorithm Project; Therapy resistant schizophrenia; Treatment algorithm

Indexed keywords

BENZAMIDE DERIVATIVE; BROMPERIDOL; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LEVODOPA; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PROTIRELIN; QUETIAPINE; RISPERIDONE; ZOTEPINE;

ALGORITHM; ARTICLE; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; JAPAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0033386592     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509909068395     Document Type: Article

References (50)

1. Zarate XA, Daniel DG, Kinon BJ et al (1995) Algorithms for the treatment of schizophrenia. Psychopharmacol Bull 31: 461-7.
2. Sato M (1995) Algorithm for schizophrenia in Japan. Psychopharmacol Bull 31: 501-4.
3. Kusumi I, Koyama T (1998) Algorithm for the treatment of neuroleptics-induced acute side effects (in Japanese). In: Sato M, Higuchi T, Yamawaki N (eds) Algorithms for the treatment of schizophrenia and mood disorders. Tokyo: Seiwasyoten 27-33.
4. Akiyama K (1998) Algorithm for the treatment of neuroleptic-induced tardive side effects (in Japanese). In: Sato M, Higuchi T, Yamawaki N (eds) Algorithms for the treatment of schizophrenia and mood disorders. Tokyo: Seiwasyoten 34-50.
5. Jobson KO, Potter WZ (1995) International psychopharmacology algorithm project report. Psychopharmacol Bull 31: 457-60.
6. Sato M, Higuchi T, Yamawaki N (eds) (1998) Algorithms for the treatment of schizophrenia and mood disorders (in Japanese). Seiwa-syoten, Tokyo.
7. Yagi G (1993) Pharmacotherapeutics of schizophrenia on neohippocratic viewpoint (in Japanese). Kanehara Co., Ltd., Tokyo.
8. Breier A, Wolkowitz OM, Doran AR et al (1987) Neuroleptic response of negative and positive symptoms in schizophrenia. Am J Psychiatry 144: 1549-55.
9. Kan R, Watanabe M, Kumashiro H (1991) The rational use of psychotropic drugs in pregnant women (in Japanese). Japn J Clin Psychiatry 20: 303-8.
10. Okazaki Y, Ota T, Nakayasu N (1983) A critical review of treatment with high doses of neuroleptics in schizophrenia (in Japanese). Japn J Neuropsychopharmacol 5: 411-25.
11. Tasman A, Murphy DL (1991) New development in the pharmacotherapy of schizophrenia. In: Tasman A, Murphy DL (eds) American Psychiatric Press Review of Psychiatry 10, Washington, D.C.: American Psychiatric Press.
12. Otsuki S (1993) Rational selection of antipsychotics in the treatment of schizophrenia (in Japanese). Japn J Psychiat Treat 8: 3-10.
13. Murasaki M (1995) Preclinical and clinical pharmacology of risperidone (in Japanese). Japn J Neuropsychopharmacology 17: 599-620.
14. Tsukijima K, Yasuda M (1996) Utilization of convulsive ECT on visit to patients with severe somatic complications in general hospital (in Japanese). Seishin Igaku 38: 423-5.
15. Kumamoto S, Kunishige K (1997) The present status of electroconvulsive therapy at Department of Neuropsychiatry in a public hospital (in Japanese). Japn J Clin Psychiatry 26: 611-21.
16. Salzman C (1980) The use of ECT in the treatment of schizophrenia. Am J Psychiatry 137: 1032-41.
17. Ito M, Hujii Y (1983) Psychotropic polypharmacy in Japan (in Japanese). Japn J Neuropsychopharmacology 5: 149-84.
18. Kamijima K (1986) Combination therapy of antipsychotics with benzodiazepine derivatives, antidepressants and lithium (in Japanese). Japn J Psychiat Treat 1: 23-32.
19. Little JD, Taghave EH (1991) Disinhibition after lorazepam augmentation of antipsychotic medication. Am J Psychiatry 148: 1099 (letter).
20. McEvoy JP, Stiller RL, Farr R (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses. A pilot study. J Clin Psychopharmacol 6: 133-38.
21. Yagi G (1989) Pharmacotherapy of acute schizophrenia (in Japanese). In: Yagi G (ed) Seishinka Mook. Tokyo: Kanehara Co., Ltd.
22. Someya T, Hirokane G, Ozeki Y et al (1996) The present circumstances and the critical issues of therapeutic drug monitoring of haloperidol (in Japanese). Seishin Igaku 38: 835-42.
23. Hirokane G, Someya T, Shibasaki M et al (1996) The inter-individual difference of bromperidol metabolism and its relationship to clinical effects (in Japanese). Japn J Clin Psychiatry 25: 1227-37.
24. Chouinard G, Jones B, Remington G et al (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25-40.
25. Kane JM, Honigfeld G, Singer J et al (1988) Clozapine for the treatment-resistant schizophrenia. A double blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 769-96.
26. Brenner HD, Debcker DSJ, Goldstein MJ et al (1990) Defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 551-60.
27. Ito M (1995) Pharmacotherapy of schizophrenia (in Japanese). Seishin Igaku 27: 521-30.
28. Kasper S (ed) (1997) European Algorithm Project. Int J Psych Clin Pract 1 (suppl.1): S1-S30.
29. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440-452.
30. Uno M (1987) Pharmacotherapy of chronic schizophrenia (in Japanese). Japn J Clin Psychiatry 6: 1571-9.
31. Uchimura H, Kuroki T (1993) Efficacy and limitation of pharmacotherapy of main psychiatric disorders (in Japanese). In: Yagi G (ed) Seishinka Mook. Tokyo: Kanehara Co. Ltd. 253-61.
32. Van Putten T, Marshall BD, Liberman R et al (1993) Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 29: 315-20.
33. Hirsch SR, Barnes TRE (1994) Clinical use of high-dose neuroleptics. Br J Psychiatry 164: 94-6.
34. Hogarty JMC, Itil TM, Keskiner A (1995) Pharmacotherapy of impaired effect in recovering schizophrenic patients. Arch Gen Psychiatry 52: 29-41.
35. Hayashi O, Miyoshi S, Higashimura T et al (1983) Blood concentration and clinical effects of haloperidol therapy in combination with levomepromazine (in Japanese). Japn J Neuropsychopharmacol 1: 41-7.
36. Growe GA, Crayton JW, Klass DB et al (1979) Lithium in chronic schizophrenia. Am J Psychiatry 136: 454-55.
37. Carman JS, Bigelow LB, Wyatt RJ (1981) Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 42: 124-28.
38. Small JG, Kellams JJ, Milstein V et al (1975) A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 132: 1315-17.
39. Jinpo M (1985) Combined therapy with lithium for schizophrenia (in Japanese). Japn J Clin Psychiatry 14: 287-94.
40. Okuma T, Yamashita I, Takahashi R et al (1989) A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Arch Psychiatry Scand 80: 250-9.
41. Klein E, Bental E, Lerer B (1984) Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. Arch Gen Psychiatry 41: 165-70.
42. Tsuneizumi T; Aoba A, Yamaguchi N et al (1986) The effect of carbamazepine on haloperidol plasma neuroleptic level (in Japanese). Japn J Neuropsychopharmacol 8: 667-73.
43. Kidron R, Averbuch I, Klein E et al (1985) Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 20: 219-22.
44. Inanaga K, Nakazawa Y, Tachibana H et al (1978) Behavioral effects of L-Dopa in schizophrenia (in Japanese). Seishin Igaku 20: 877-89.
45. Shiina K, Kamijima K, Kuriowa T et al (1993) The use of mianserin hydrochloride with neuroleptics in chronic schizophrenic patients (in Japanese). Japn J Clin Psychiatry 22: 89-99.
46. Kuniyoshi M, Inanaga K, Okamoto K et al (1994) The effects of sertiptiline maleate (Tecipul) on negative symptoms of schizophrenia (in Japanese). Japn J Psychiat Treat 9: 1273-78.
47. Morinobu S, Sagawa K, Higashitani Y (1989) The therapeutic effects of L-DOPS in negative symptom in schizophrenia (in Japanese). Japn J Psychiatry 18: 1895-1900.
48. Yamauchi I (1976) Clinical application of thyrotropin-releasing hormone for the treatment of schizophrenia. Clin Psychiatry 18: 427-35.
49. Johns CA, Thompson JW (1995) Adjunctive treatments in schizophrenia: pharmacotherapy and electro-convulsive therapy. Schizophr Bull 21: 607-19.
50. Smith K, Surphlis WRP, Gynther MD et al (1967) ECT - chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. J Nerv Ment Dis 144: 284-90.